Ruth Swann

5.0k total citations · 1 hit paper
44 papers, 2.7k citations indexed

About

Ruth Swann is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ruth Swann has authored 44 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ruth Swann's work include Global Cancer Incidence and Screening (11 papers), Melanoma and MAPK Pathways (9 papers) and Colorectal Cancer Screening and Detection (7 papers). Ruth Swann is often cited by papers focused on Global Cancer Incidence and Screening (11 papers), Melanoma and MAPK Pathways (9 papers) and Colorectal Cancer Screening and Detection (7 papers). Ruth Swann collaborates with scholars based in United Kingdom, United States and Australia. Ruth Swann's co-authors include Kathy S. Albain, David H. Johnson, Colum J Smith, Frances A. Shepherd, Valerie W. Rusch, Andrew T. Turrisi, David R. Gandara, Willard A. Fry, Robert C. Miller and Robert B. Livingston and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Ruth Swann

42 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

2009 999 citations Kathy S. Albain, Ruth Swann et al. The Lancet profile →

Peers

Countries citing papers authored by Ruth Swann

Since Specialization

Citations

This map shows the geographic impact of Ruth Swann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Swann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Swann more than expected).

Fields of papers citing papers by Ruth Swann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Swann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Swann. The network helps show where Ruth Swann may publish in the future.

Co-authorship network of co-authors of Ruth Swann

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Swann. A scholar is included among the top collaborators of Ruth Swann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Swann. Ruth Swann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CT and MRI activity in England: insights from the diagnostic imaging dataset 2025 ·Clinical Radiology ·Ruth Swann, (unknown), Kevin J. Roberts, (unknown), (unknown), Fahmina Fardus‐Reid, L Ironmonger, Giles Maskell, Jon Shelton, Michael J. Richards	0
2	Predictors and consequences of different pathways to emergency diagnosis of cancer in England: Evidence from linked national audit and cancer registration data 2024 ·Cancer Epidemiology ·Ruth Swann, Georgios Lyratzopoulos, Greg Rubin, Lucy Elliss‐Brookes, Sean McPhail	1
3	Factors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis Audit 2024 ·British Journal of General Practice ·Samuel WD Merriel, (unknown), (unknown), Ruth Swann, Sean McPhail, Greg Rubin, Georgios Lyratzopoulos, Gary Abel	1
4	National Cancer Diagnosis Audits for England 2018 versus 2014: a comparative analysis 2023 ·British Journal of General Practice ·Ruth Swann, Sean McPhail, Gary Abel, (unknown), (unknown), Sara Hiom, Georgios Lyratzopoulos, Greg Rubin	11
5	Pre-Referral Primary Care Blood Tests and Symptom Presentation before Cancer Diagnosis: National Cancer Diagnosis Audit Data 2023 ·Cancers ·(unknown), Gary Abel, Ruth Swann, Sarah F. Moore, Sean McPhail, Greg Rubin, Georgios Lyratzopoulos	3
6	The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit 2023 ·British Journal of Cancer ·(unknown), Matthew Barclay, Ruth Swann, Sean McPhail, Greg Rubin, Gary Abel, Georgios Lyratzopoulos	10
7	Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data 2022 ·British Journal of General Practice ·(unknown), Minjoung Monica Koo, Gary Abel, Ruth Swann, Sean McPhail, Greg Rubin, Georgios Lyratzopoulos	7
8	The prevalence of chronic conditions in patients diagnosed with one of 29 common and rarer cancers: A cross-sectional study using primary care data 2020 ·Cancer Epidemiology ·Minjoung Monica Koo, Ruth Swann, Sean McPhail, Gary Abel, Cristina Renzi, Greg Rubin, Georgios Lyratzopoulos	12
9	Impact of geography on Scottish cancer diagnoses in primary care: Results from a national cancer diagnosis audit 2020 ·Cancer Epidemiology ·Peter Murchie, Rosalind Adam, (unknown), Sarah Smith, (unknown), Ruth Swann, (unknown), David Weller	6
10	Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study 2019 ·The Lancet Oncology ·Minjoung Monica Koo, Ruth Swann, Sean McPhail, Gary Abel, Lucy Elliss‐Brookes, Greg Rubin, Georgios Lyratzopoulos	158
11	The frequency, nature and impact of GP-assessed avoidable delays in a population-based cohort of cancer patients 2019 ·Cancer Epidemiology ·Ruth Swann, Georgios Lyratzopoulos, Greg Rubin, (unknown), Sean McPhail	24
12	Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion 2016 ·British Journal of Cancer ·Simon Fry, C. Robertson, Ruth Swann, Miriam Dwek	23
13	Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy 2013 ·Clinical Cancer Research ·Neil R. Smith, Dawn Baker, Matthew R. Farren, Aurélien Pommier, Ruth Swann, Xin Wang, (unknown), Karen McDaid, Jane Kendrew, Chris Womack, Stephen R. Wedge, Simon T. Barry	111
14	The DietCompLyf study: A prospective cohort study of breast cancer survival and phytoestrogen consumption 2013 ·Maturitas ·Ruth Swann, (unknown), Louiza S. Velentzis, (unknown), Susan Dutton, Angela A. Mulligan, Jayne V. Woodside, Marie M. Cantwell, Anthony J. Leathem, C. Robertson, Miriam Dwek	20
15	Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers 2010 ·Clinical Cancer Research ·Neil R. Smith, Dawn Baker, Neil H. James, Kirsty Ratcliffe, Martin Jenkins, Susan Ashton, (unknown), Ruth Swann, Neil Gray, Anderson J. Ryan, Juliane M. Jürgensmeier, Chris Womack	197
16	Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial breakdown → 2009 ·The Lancet ·Kathy S. Albain, Ruth Swann, Valerie W. Rusch, Andrew T. Turrisi, Frances A. Shepherd, Colum J Smith, Yuhchyau Chen, Robert B. Livingston, Richard H. Feins, David R. Gandara, Willard A. Fry, Gail Darling, David H. Johnson, Mark R. Green, Robert C. Miller, (unknown), W. Sause, James D. Cox	999
17	Effect of Amifostine on Response Rates in Locally Advanced Non–Small-Cell Lung Cancer Patients Treated on Randomized Controlled Trials: A Meta-Analysis 2007 ·International Journal of Radiation OncologyBiologyPhysics ·Loren K. Mell, Renuka Malik, Ritsuko Komaki, Benjamin Movsas, Ruth Swann, Corey J. Langer, D. Antonadou, Michael I. Koukourakis, Arno J. Mundt	27
18	Increasing Tumor Volume is Predictive of Poor Overall and Progression-Free Survival: Secondary Analysis of the Radiation Therapy Oncology Group 93-11 Phase I-II Radiation Dose-Escalation Study in Patients with Inoperable Non–Small-Cell Lung Cancer 2007 ·International Journal of Radiation OncologyBiologyPhysics ·Maria Werner‐Wasik, Ruth Swann, Jeffrey D. Bradley, Mary V. Graham, Bahman Emami, James A. Purdy, William T. Sause	86
19	Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13 2006 ·Journal of Clinical Oncology ·Elizabeth Elliott, James R. Wright, Ruth Swann, (unknown), Cristiane Takita, M. Kara Bucci, Adam S. Garden, Harold Kim, Eugen B. Hug, Janice Ryu, Michael J. Greenberg, Jerrold P. Saxton, Kian Ang, Lawrence Berk	89
20	Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97–12 2005 ·International Journal of Radiation OncologyBiologyPhysics ·Ritsuko Komaki, Ruth Swann, David S. Ettinger, Bonnie S. Glisson, Alan B. Sandler, Benjamin Movsas, John H. Suh, Roger W. Byhardt	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact